REG - ValiRx PLC - Commercial update

ValiRxAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250826:nRSZ5461Wa&default-theme=true

RNS Number : 5461W  ValiRx PLC  26 August 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

Commercial update

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, announces that, further to
the announcement on 3 April 2025, the Company has established a new wholly
owned subsidiary Blue Ribbon Bio Limited ("Blue Ribbon").

Blue Ribbon has been incorporated to house all Prostate Cancer associated
assets from ValiRx Plc which will initially consist of existing Intellectual
Property for Val201, exclusively licensed to ValiRx by Cancer Research
Horizons in 2010. The Company plans to file new application-based patents for
Val201 which will be held by Blue Ribbon.

 

A detailed technical and market assessment has been conducted for Val201 as
part of a comprehensive review of ValiRx's current and potential assets and
concluded that there is a still a strong rationale for Val201 within the
treatment pathway for prostate cancer. A critical path plan to expedite
validation of improvements to Val201 to create additional value, extend patent
coverage and position for partnering is now in place.

 

A notice of allowance has also been received for Canadian "Medical Use" patent
(application No. 2,853,671) for the treatment of non-cancerous conditions
relating to the use of the Val201 peptide in endometriosis (Val301).

 

Mark Eccleston, CEO of ValiRx commented "We have an opportunity to build a
broader prostate cancer focussed portfolio based on current and future pan
cancer assets that can be applied in this indication. Having worked on the
original pre-clinical development of Val201, I am pleased that there is still
a market opportunity for this asset, and we intend to rapidly complete the
planned work required to get this back into the clinic in new and improved
form. This will build on the initial data package and key opinion leader
feedback developed in the earlier clinical trial and development will be
applicable to all applications of the peptide, including in endometriosis, so
I also pleased to announce notification that our Canadian patent will be
granted. We will leverage the combined experience and resources of our tCRO,
Inaphaea Biolabs, including the prostate cancer Patient Derived Models that we
are developing in partnership with the Open University, with the advanced non
animal 3D-culture testing capabilities we have brought in through our
capability partners. Several of our current assets, those in our repurposing
program with Dominion and other assets under consideration for evaluation and
in-licensing can be applied across various stages of prostate cancer as well
as our core focus in women's health. By ringfencing these assets in a
portfolio approach we believe that we can create significant value and attract
partners for clinical development."

 

Tony Hickson, Chief Business Officer of Cancer Research Horizons, commented:
"Cancer Research Horizons is committed to bringing new drugs to market and
supports the development of drugs at all stages, especially in areas of high
unmet clinical need. Hormone therapies such as Enzalutamide and Abiraterone
have transformed prostate cancer treatment, but most patients eventually
become resistant to this form of therapy and there remains an unmet need for
new drugs to overcome drug resistance. Val201 has a unique mechanism of action
and can be positioned to address these resistant forms of cancer, as well as
potentially earlier stages of the disease to mitigate the side effects seen
under hormone ablation. We are pleased that ValiRx and Blue Ribbon Bio will
continue with the development of a version of the therapy optimised for
clinical impact."

 

The Directors of the Company take responsibility for this announcement.

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/0y5LzP

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPPUAARUPAGAA